Evidence map›Paper›PMID 25502755›Full record

ArticleNature communications2014

An integrated epigenomic analysis for type 2 diabetes susceptibility loci in monozygotic twins.

Wei Yuan, Yudong Xia, Christopher G Bell, Idil Yet, Teresa Ferreira, Kirsten J Ward, Fei Gao, A Katrina Loomis, Craig L Hyde, Honglong Wu and 14 more

Open access · hybridAbstract read
In one paragraph

Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Epigenome-wide Association of DNA Methylation in Whole Blood With Bone Mineral Density.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017
    Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?International journal of molecular sciences · 2021
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 5 countries.

Wei YuanDepartment of Twin Research &Genetic Epidemiology, King's College London, London SE1 7EH, UK.
Yudong XiaBGI-Shenzhen, Shenzhen 518083, China.
Christopher G BellDepartment of Twin Research &Genetic Epidemiology, King's College London, London SE1 7EH, UK.
Idil YetDepartment of Twin Research &Genetic Epidemiology, King's College London, London SE1 7EH, UK.
Teresa FerreiraWellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.
Kirsten J WardDepartment of Twin Research &Genetic Epidemiology, King's College London, London SE1 7EH, UK.
Fei GaoBGI-Shenzhen, Shenzhen 518083, China.
A Katrina LoomisPfizer Worldwide Research and Development, Groton, Connecticut 06340, USA.
Craig L HydePfizer Worldwide Research and Development, Groton, Connecticut 06340, USA.
Honglong WuBGI-Shenzhen, Shenzhen 518083, China.
Hanlin LuBGI-Shenzhen, Shenzhen 518083, China.
Yuan LiuBGI-Shenzhen, Shenzhen 518083, China.
Kerrin S SmallDepartment of Twin Research &Genetic Epidemiology, King's College London, London SE1 7EH, UK.
Ana ViñuelaDepartment of Twin Research &Genetic Epidemiology, King's College London, London SE1 7EH, UK.
Andrew P Morris1] Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK [2] Department of Biostatistics, University of Liverpool, Liverpool L69 3GA, UK.
María BerdascoCancer Epigenetics and Biology Program (PEBC), Hospital Duran i Reynals, Barcelona 08908, Spain.
Manel Esteller1] Cancer Epigenetics and Biology Program (PEBC), Hospital Duran i Reynals, Barcelona 08908, Spain [2] Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia 08907, Spain [3] Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia 08010, Spain.
M Julia BrosnanPfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, USA.
Panos Deloukas1] William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK [2] King Abdulaziz University, Jeddah 22254, Saudi Arabia.
Mark I McCarthy1] Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK [2] Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, oxford OX3 7LE, UK [3] Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LE, UK.
Sally L JohnPfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, USA.
Jordana T BellDepartment of Twin Research &Genetic Epidemiology, King's College London, London SE1 7EH, UK.
Jun Wang1] BGI-Shenzhen, Shenzhen 518083, China [2] King Abdulaziz University, Jeddah 22254, Saudi Arabia [3] Department of Biology, University of Copenhagen, Copenhagen DK-2200, Denmark [4] The Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen DK-2200, Denmark.
Tim D SpectorDepartment of Twin Research &Genetic Epidemiology, King's College London, London SE1 7EH, UK.
King's College London · GBBGI Group (China) · CNPfizer (United States) · USCentre for Human Genetics · GBDuran i Reynals Hospital · ESNovo Nordisk Foundation · DKQueen Mary University of London · GB

Funding

European Research Council 250157Wellcome Trust 098017Wellcome Trust 098381
6 · The paper itself

Abstract

DNA methylation has a great potential for understanding the aetiology of common complex traits such as Type 2 diabetes (T2D). Here we perform genome-wide methylated DNA immunoprecipitation sequencing (MeDIP-seq) in whole-blood-derived DNA from 27 monozygotic twin pairs and follow up results with replication and integrated omics analyses. We identify predominately hypermethylated T2D-related differentially methylated regions (DMRs) and replicate the top signals in 42 unrelated T2D cases and 221 controls. The strongest signal is in the promoter of the MALT1 gene, involved in insulin and glycaemic pathways, and related to taurocholate levels in blood. Integrating the DNA methylome findings with T2D GWAS meta-analysis results reveals a strong enrichment for DMRs in T2D-susceptibility loci. We also detect signals specific to T2D-discordant twins in the GPR61 and PRKCB genes. These replicated T2D associations reflect both likely causal and consequential pathways of the disease. The analysis indicates how an integrated genomics and epigenomics approach, utilizing an MZ twin design, can provide pathogenic insights as well as potential drug targets and biomarkers for T2D and other complex traits.

Indexed as

DNA MethylationEpigenesis, GeneticGenetic LociGenome, HumanBiomarkersCase-Control StudiesCaspasesCpG IslandsDiabetes Mellitus, Type 2EpigenomicsGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansInsulinMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinNeoplasm ProteinsBiomarkersCaspasesGPR61 protein, humanInsulinMALT1 protein, humanMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinNeoplasm ProteinsNerve Tissue ProteinsPRKCB protein, humanProtein Kinase C betaReceptors, G-Protein-CoupledTaurocholic Acid

Identifiers

PMID25502755
PMCPMC4284644
OpenAlexW2032662504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.